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Macrocerebellum is a rare condition characterized by enlargement of
thecerebellumwithconservationofoverall shapeandcytoarchitecture
[Poretti et al., 2012]. Despite varied reports on syndromic and non-
syndromic casesofmacrocerebellum, theunderlyinggenetic etiologies
remain largely unknown.We report on a childwithmacrocerebellum,
epilepsy, cognitive impairment, dysautonomia, gut malrotation, and
poor gut motility. We characterized the phenotype in this patient,
evaluated her with array CGH, and compared her deletion and
phenotype with other reports of patients with overlapping deletions.
CLINICAL REPORT
A 3-year-8-month-old girl was referred to the University of Mich-
igan Pediatric Genetics service with a history of macrocerebellum,2014 Wiley Periodicals, Inc.epilepsy, apparent intellectual disability, dysautonomia, gut mal-
rotation, and poor gut motility. She was born at full term gestation
after an uncomplicated pregnancy to a gravida 6 para 4 mother.
Birth parameters included weight 3.4 kg (75th centile), length
51 cm (75th centile), and OFC 35 cm (75th centile). Initial
concerns raised at 2–3 weeks of age included persistent screaming,
prominent tongue thrusting, and hypotonia. She had been evalu-
ated by the Beaumont Hospital Pediatric Neurology service at
2 months of age, when cranial MRI showed an enlarged cerebellum
(Fig. 1). She underwent clinical genetic evaluation at Beaumont at
6 months of age, which included a genomic microarray analysis2062
FIG. 1. A: Sagittal T1 weighted midline image at the age of 2 months demonstrates increased cerebellar volume as evidenced by upward peak
of the tentorium (white arrow). Increased volume of cerebellar vermis is also noted (black arrow). B: Normal age-matched control at 2 months.
C: Off-midline image at the age of 3 years 7 months again demonstrates upward peaking of the tentorium (white arrow) along with relative
increased amount of cerebellar gray matter in comparison to white matter volume (black arrows). D: Normal age matched control at 3 years 7
months.
SEELEY ET AL. 2063usingNimblegenCGX-3TM135 Koligonucleotide array (v2.0 based
on UCSC 2006 hg 18 assembly). This study showed a 983.10 kb
deletion of chromosome 16q24.1–q24.2 (85,457,391–86,440,486;
hg18). The proximal normal array feature is 85,454,268 and the
distal normal array feature is 86,529,493. The array features for the
proximal and distal deletion boundaries are 85,457,391 and
86,440,426, respectively.
Fluorescence in situ hybridization (FISH) analysis of metaphase
cells using aBACclone,which localized to thedeleted region (RP11-
178L8), confirmed thedeletion.TheFISH studies on100 interphase
nuclei from each parent showed no evidence of deletion, consistent
with apparently de novo occurrence. The 16q24.1–q24.2 deletion
resulted in loss of four OMIM genes: FBXO31,MAP1LC3B, JPH3,
and SLC7A5 as well as three non-OMIM genes; C16orf95,
ZCCHC14, and KLHDC4 (Fig. 2). The deletion was considered
to be likely clinically significant based on the size of the deletion and
its gene content.
Due to persistent discomfort and constipation, abdominal lapa-
roscopic surgery was performed at seven months and showed a
duodenal hernia and gut malrotation. She developed significantly
reduced bowel motility and symptoms of autonomic dysregulation
including decreased heart rate variability during wakefulness, lackof ventilatory and cardiovascular responses to mild daytime hyp-
oxemia, acrocyanosis, intermittent fevers, and anisocoria. Normal
enteric ganglion cells onbiopsy ruledoutHirschsprungdisease, and
sequencing of the RET and PHOX2B genes was normal.
Developmental history was positive for mild global develop-
mental delay. She rolled over by 5 months, crawled by 12 months,
and walked by the age of 22 months. Shortly after turning 3 years
old, she began using 2–3 word combinations and speaking in short
sentences. Overall, she was noted to have significant difficulty with
motor planning and word recall. She developed seizures at
15 months.
Due to the progression of abdominal distention, feeding intol-
erance, and hypotonia, a mitochondrial evaluation was pursued. A
rectus abdominus muscle biopsy at age 3 years showed grouped
atrophy of muscle fibers, suggestive of denervation. Carnitine was
low (23.6mmol/ml; normal 33.9–69.1) and free carnitine was
14.2mmol/ml (normal 30.2–56.8). Creatine phosphokinase
(CPK) was 326U/L (normal 30–250). Electron transport chain
analysis at theCenter for InheritedDisorders of EnergyMetabolism
(Case Western Reserve University School of Medicine) indicated
normal activity of ETC complex 3, but mild defects in complexes 1,
2, and 4. Mitochondrial DNA genome sequencing showed homo-
FIG. 2. A schematic representation of the 16q24.1–q24.2 deletion in this clinical report and the RefSeq genes within the region. The asterisk
denotes OMIM genes.
2064 AMERICAN JOURNAL OF MEDICAL GENETICS PART Aplasmy for a variant of unclear significance, m.11253T>C,
p.Ile165Thr in the ND4 gene, which encodes a structural subunit
of complex 4.
She had a history of mildly elevated lactate, pyruvate, and CPK;
however, these were normal on repeat assessment at 3 years and
10 months of age. Additional biochemical evaluation at 3 years 10
months included plasma amino acids, urine organic acids, and
carnitine combinationprofile, all ofwhichwerenormal. Thymidine
phosphorylase enzyme assay to evaluate for mitochondrial neuro-
gastrointestinal encephalopathy (MNGIE) was normal. Testing for
congenital disorders of glycosylation, including N-glycan and O-
glycan screening, was normal. Sequence analysis of epilepsy-asso-
ciated genes at 3 years 3months (Courtagen Life Sciences,Woburn,
MA) showed no pathogenic mutations in STIL, ATR, VPS13B,
UBE3A, SLC25A33, CACNA1S, ACAD11, SIRT5, MUT, CFTR,
DUSP26, LIPT2, METTL17, SPTLC2, EARS2, and ACO2 genes.
Physical examination at age 3 years 10 months showed weight
12.8 kg (5th centile), height 93 cm (5th centile), and OFC
50.2 cm (55th centile). Facial features were notable for bilateral
mild epicanthal folds and a deeply grooved philtrum. Abdominal
exam showed a gastrostomy tube with no surrounding erythema,
swelling, or drainage. Neurologic exam demonstrated central hy-
potonia with normal strength in the extremities, wide based gait,
hyporeflexia, and past-pointing on finger-nose examination. All
other physical features were normal. A renal ultrasound performed
at 3 years 10 months was normal.Noncontrast cranial MRI at 3 years 7 months of age demon-
strated diffuse symmetrical enlargement of the cerebellum with
thickened but symmetric prominence of the gray matter most
noticeable along the lateral and inferior aspects the cerebellar
hemispheres (Fig. 1). The patient was imaged on a 3T Philips
Ingenia MRI system using a 15-channel receive head coil. T1-
weighted 3D-MPRAGE imaging was used to obtain the volu-
metric imaging data. Cerebellar volumetric analysis and seg-
mentationwas performedusing FreeSurfer, version 5.3.0 (http://
surfer.nmr.mgh.harvard.edu). The gray matter cerebellar vol-
ume was 94 cm3 and the white matter cerebellar volume was
31 cm3 for a total volume of 125 cm3. Based on normative
imaging data, the volume of the cerebellum is equivalent to
that of a 17–18 year old female [Brain Development
Cooperative, 2012]. No underlying parenchymal signal abnor-
malities were identified. Cerebellar tonsils extended to the upper
limit of normal at approximately 6mm below the level of the
foramen magnum and were morphologically normal. Supra-
tentorial ventricles and cortical sulci were age-appropriate. No
parenchymal signal abnormalities were identified and myelina-
tionpattern appeared normal. Therewere nomidline shifts,mass
effect, or hydrocephalus. Normal skull base arterial flow voids
were present. No abnormal contrast uptake was seen. Magnetic
Resonance spectroscopy performed over the basal ganglia and
centrum semiovale showed no evidence of altered metabolite
ratios. No lactate peak was noted.
SEELEY ET AL. 2065DISCUSSION
A comparison of this child’s features to those reported with
16q24.1–q24.2 deletions did not show any other reports of macro-
cerebellum, but included three individuals with similar deletions
andmacrocephaly [Butler et al., 2012; Handrigan et al., 2013]. This
may reflect under-reporting of macrocerebellum as a radiologic
observation, or modifying environmental or genetic factors.
Macrocerebellum has been reported as part of several genetic
syndromes, including macrocephaly-capillary malformation syn-
drome [Conway et al., 2007a,b], Sotos syndrome [Schaefer
et al., 1997], Williams syndrome [Jones et al., 2002], Costello
syndrome [Gripp et al., 2010, 2011], Alexander disease [Torreman
et al., 1993; van der Knaap et al., 2005], fucosidosis [Kau et al.,
2011], and Lhermitte–Duclos syndrome [Milbouw et al., 1988;
Nowak and Trost, 2002; Perez-Nunez et al., 2004]. In syndromic
conditions that present with macrocerebellum, cerebellar growth
often exhibits a distinct developmental pattern. Patients with
Costello syndrome, macrocephaly-capillary malformation syn-
drome, and Lhermitte–Duclos syndrome all demonstrate gradual
cerebellar enlargement. In patients with Alexander disease and
fucosidosis where macrocerebellum has been reported, subsequent
cerebellar atrophy was also identified [Inui et al., 2000; van der
Knaap et al., 2005]. In the patient reported here, the overall
proportion of cerebellum to cerebrum remained stable over time.
Macrocerebellum has been reported as an isolated occurrence in
only ten individuals [Bodensteiner et al., 1997; Pichiecchio
et al., 2011; Poretti et al., 2012]. These reports described additional
clinical features that were not present in the child described here.
Bodensteiner et al. [1997] described four patients with macro-
cerebellumanddelayedmyelinationof the cerebralwhitematter, all
of whom presented with global developmental delay, marked early
hypotonia, and delayedmaturation of the visual systemmanifested
by apraxia of gaze and delayed maturation of fixing and following.
Pichiecchio et al. [2011] reported the first longitudinal assessment
of an individual with cerebellar enlargement, demonstrating in-
creased cerebellar volumebetweenbirth and19months of age.They
hypothesized that isolated enlargement of the cerebellum may not
be a primary manifestation but rather an epiphenomenon second-
ary to disturbed cerebral involvement. Finially, Poretti et al. [2012]
demonstrated thickeningof the cortical graymatterof the cerebellar
hemispheres and macrocerebellum in five patients. These individ-
uals differed in dysmorphic features and extracerebral organ in-
volvement, but all demonstrated hypotonia and delays in cognitive
development. These varied features associated with macrocerebel-
lum suggest broad clinical variability in expression and potentially
substantial genetic heterogeneity; indeed, the child had a history of
generalized weakness but no overt ataxia.
In the child described here, deletion of 983.1 kb of genomic
material on chromosome 16q24.1q24.2 led to loss of one copy each
of four OMIM genes and three non-OMIM genes (Table I). Han-
drigan et al. [2013] reported a series of patients with autism
spectrum disorder, intellectual disability, congenital renal malfor-
mation, and a microdeletion within band 16q24.2. The present
patient’s deletion was not identical to any of those reported in their
study; however, it did overlap on the centromeric side with their
minimally deleted region [Handrigan et al., 2013]. This overlapincluded the genesFBXO31,MAP1LC3B,C16orf95, andZCCHC14.
Of interest, none of the patients they reportedwere reported tohave
macrocerebellum, although three individuals had macrocephaly.
While this might suggest that macrocerebellum is associated with
loss of JPH3or SLC7A5,macrocerebellummayhave beenpresent in
those patients but not detected and reported.
The International Standards for Cytogenomic Arrays Consor-
tium (ISCA) database contains no deletions identical to that found
in this study. Five smaller deletions that overlap the deleted region
in this child are present in ISCA and are considered to be of
unknown clinical significance. The ISCA database also documents
two pathogenic deletions (2 and 9Mb) associated with develop-
mental delay, which overlap the deleted region reported here
(including the distal portion of the deleted region). Also included
in ISCA is a 1Mb deletion (nearly identical to that reported here)
considered of uncertain clinical significance but likely pathogenic.
The phenotype listed for that case ismacrocephaly. In none of these
patients was macrocerebellum mentioned in the phenotypic
description.
Recent data about the expression pattern and function of these
genes provides evidence that haploinsufficiency of one or more of
these genes may contribute to the macrocerebellum phenotype.
FBXO31 is a member of the Fbox protein family, and regulates the
cell cycle via the FBXO31–SCF (Skp1, Cullin1, Fbox protein) E3
ubiquitin ligase degradation pathway [Kumar et al., 2005; Santra
et al., 2009]. The FBXO31–SCF complex regulates cultured neuro-
nal morphogenesis and axonal outgrowth [Vadhvani et al., 2013].
Interestingly, RNAi knockdown of FBXO31 in rat cerebella im-
paired the ability of granule cell neurons to migrate out of the
external granule layer [Vadhvani et al., 2013]. These observations
suggest thatFBXO31mayplay a critical role in cellmigrationduring
cerebellar development.
MAP1LC3B, another gene in the deletion interval, encodes the
microtubule associated protein 1 light chain 3 beta, a marker for
induction of autophagy in tissues [Mizushima et al., 2004].
MAP1LC3B is highly expressed in the cerebellum [Cann
et al., 2008]. Interestingly, autophagy and neurodegeneration are
both implicated in seizure pathogenesis, and it is possible that
haploinsufficiency for MAP1LC3B contributed directly to the
cerebellar overgrowth and seizure phenotype in the patient
reported here.
JPH3 (Junctophillin-3) encodes a member or the Junctophillin
family of transmembrane proteins that span the endoplasmic
reticulum and communicate with the cell surface through ion
channels [Takeshima et al., 2000]. JPH3 and another family mem-
ber, JPH4, are expressed throughout the brain in similar cell
populations including cerebellar Purkinje cells [Nishi
et al., 2003]. Neither JPH3 single mutant nor JPH3/JPH4 double
mutantmice exhibit abnormalities in cerebellar structure; however,
both mouse strains suffer from coordination and learning defects
[Nishi et al., 2002;Kakizawa et al., 2007; Seixas et al., 2012].Notably,
CTG repeat expansions (>41) in the JPH3 gene cause Huntington
disease-like 2 phenotypes [Wilburn et al., 2011].
SLC7A5 (alsoknownasLAT1) resides in thedeletion interval and
encodes a neutral amino acid transporter expressed inmicrovessels
and proliferating progenitors in the brain [Kageyama et al., 2000].
SLC7A5 is expressed in the hippocampus, subventricular zone,
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SEELEY ET AL. 2067dentate gyrus, and cerebellum.Complete loss of Slc7a5 inmice is an
embryonic lethal [Duelli et al., 2000; Kageyama et al., 2000; Tang
et al., 2010]. SLC7A5 is also regulated in cortical tubers of patients
with tuberous sclerosis and drug resistant epilepsy [Lim
et al., 2011]. Thus, SLC7A5 may also contribute to cerebellar
development and epilepsy. Other (non-OMIM) genes in the
16q24 deletion interval include ZCCHC14, KLHDC4, and
C16ORF95, but their functions and expression patterns are
unknown.
In summary, this child has a distinctive constellation of clinical
features including macrocerebellum and a microdeletion of
16q24.1–q24.2. Further study of the expression and function of
gene(s) in the deletion interval should shed light on the underlying
etiology of macrocerebellum and provide clues about the genetic
factors that regulate cerebellar growth and development.ACKNOWLEDGMENTS
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